A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial
Robert K. Mahar, Anna McGlothlin, Michael Dymock, Todd C. Lee, Roger Lewis, Thomas Lumley, Jocelyn Mora, David J. Price, Benjamin R. Saville, Tom Snelling, Rebecca Turner, Steven Webb, Joshua S. Davis, Steven Y. C. Tong, Julie Marsh, Asha C Bowen, Matthew P. Cheng, Nick Daneman, Joshua S. Davis, Anna L. Goodman, George Heriot, Todd C. Lee, Roger Lewis, David Chien Lye, Julie Marsh, Anna McGlothlin, Zoe McQuilten, Jocelyn Mora, Susan C. Morpeth, David L. Paterson, David J. Price, Jason A. Roberts, Owen Robinson, Matthew Scarborough, Steven Y. C. Tong, Sebastiaan J. van Hal, Genevieve Walls, Steve Webb, Lynda Whiteway, Dafna Yahav
Abstract
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection. Here, we formalise the trial structure, modelling approach, and decision rules that will be used for the SNAP trial. By summarising the statistical principles governing the design, our hope is that the SNAP trial will serve as an adaptable template that can be used to improve comparative effectiveness research efficiency in other disease areas.Trial registration NCT05137119 . Registered on 30 November 2021.